Peer review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help Editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Journal for ImmunoTherapy of Cancer operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.
Authors will be able to check the progress of their manuscript at any time by logging into the journal's submission system Editorial Manager.
Official journal of
- Editorial Board
- Sign up for article alerts and news from this journal
2017 Journal Metrics
46 days to first decision for reviewed manuscripts only
46 days to first decision for all manuscripts
115 days from submission to acceptance
16 days from acceptance to publication
8.374 - 2-year Impact Factor
1.241 - Source Normalized Impact per Paper (SNIP)
2.798 - SCImago Journal Rank (SJR)
5.85 - Citescore
Social Media Impact